BioLineRx (BLRX) Current Assets (2011 - 2026)

BioLineRx's Current Assets history runs 15 years deep, the most recent figure standing at $23.7 million for Q4 2025.

• In Q4 2025, Current Assets fell 12.63% year-over-year to $23.7 million; the TTM figure through Dec 2025 stood at $23.7 million (down 12.63% YoY), while the FY2025 annual figure was $23.7 million, down 12.63% from the prior year.
• Current Assets for Q4 2025 stood at $23.7 million, down from $28.5 million in the prior quarter.
• The five-year high for Current Assets was $67.1 million in Q2 2021, with the low at $23.7 million in Q4 2025.
• The 5-year median for Current Assets is $44.2 million (2022), against an average of $43.6 million.
• The sharpest annual moves came in 2021 and 2023: Current Assets jumped 193.36% in 2021, then tumbled 50.29% in 2023.
• BioLineRx's Current Assets stood at $57.4 million in 2021, then decreased by 9.41% to $52.0 million in 2022, then slipped by 9.27% to $47.2 million in 2023, then slumped by 42.56% to $27.1 million in 2024, then retreated by 12.63% to $23.7 million in 2025.
• Business Quant data shows BLRX's Current Assets at $23.7 million in Q4 2025, $28.5 million in Q3 2025, and $31.9 million in Q2 2025.